The End Of The Road: Mirna To Cease Operations After Merger With Synlogic

Mirna Therapeutics Inc., after raising tens of millions of dollars in venture capital and research grants and going public, has reached the end of the road.

The Austin-based biotech company halted drug development last year following deaths of patients in clinical trials— now it is being acquired by a Boston-area suitor in a reverse merger.

Synlogic Inc. of Cambridge, Massachusetts, which focuses on drugs that affect bacteria in the gut, announced Tuesday its merger with Mirna (Nasdaq: MIRN), which will result in the company departing the Texas capital.

Back to news